Clinical trials: Insufficient Physical Activity
Inadequate; Pulmonary Ventilation, Newborn, Infant, Very Low Birth Weight
Nasal Noninvasive NAVA in the Very Low Birth Weight Infant
The purpose of this study is to determine if a new type of mechanical ventilation, or breathing machine (called neurally adjusted ventilatory assist or NAVA), will provide additional support to infants who were born prematurely.
- Trial name
- NCT01785563
- Testing
- Nasal NIV-NAVA
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Tarah T Colaizy
Type 2 Diabetes Mellitus
MK-0431/ONO-5435 Phase III Clinical Trial - Insulin Add-on Study for Patients With Type 2 Diabetes Mellitus
This Phase III clinical trial will examine the efficacy, safety, and tolerability of the addition of MK-0431/ONO-5435 to Japanese patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on diet/exercise…
- Trial name
- NCT00854035
- Testing
- MK-0431/ONO-5435
- Where
- 7 sites in Japan
- Volunteers
- 266 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
This study is conducted to determine the most appropriate therapeutic doses of BI 10773 in Japanese patients with T2DM at first treatment period.
- Trial name
- NCT01193218
- Testing
- BI 10773
- Where
- 32 sites in Japan
- Volunteers
- 547 people
- Sponsor
- Boehringer Ingelheim
Ankylosing Spondylitis
Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs
The goal of this research is to assess the percentage of non-responders to ≥ 2 NSAIDs candidates a biological therapy that could adequately respond to treatment with etoricoxib This study confirm the result of a previous study in…
- Trial name
- NCT01091675
- Testing
- Etoricoxib
- Where
- 14 sites in Spain
- Volunteers
- 58 people
- Sponsor
- Spanish Foundation of Rheumatology
Type 2 Diabetes Mellitus
Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
- Trial name
- NCT05666128
- Testing
- HD-6277
- Where
- South Korea
- Volunteers
- 112 people
- Sponsor
- Hyundai Pharm
Pain, Postoperative, Analgesic Requirement
Effect of Intraperitoneal and Intravenous Lignocaine on Pain Relief Following Laparoscopic Cholecystectomy
Laparoscopic Cholecystectomy is the treatment of choice for patients with symptomatic gall stones. For pain relief following laparoscopic cholecystectomy both intraperitoneal and intravenous administration of lignocaine has been…
- Conditions
- Pain, Postoperative, Analgesic Requirement, Stress Response, Return of Bowel Activity
- Trial name
- NCT01717222
- Testing
- Intraperitoneal Lignocaine, Intravenous Lignocaine
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Jawaharlal Institute of Postgraduate Medical Education & Research
Rheumatoid Arthritis
A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
This open-label single-arm study will evaluate the safety, tolerability and efficacy of tocilizumab [RoActemra/Actemra] in patients with moderate to severe rheumatoid arthritis who experience an inadequate clinical response to a…
- Trial name
- NCT01089023
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 9 sites in Bahrain, Iran and 3 more
- Volunteers
- 95 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes
Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone
This protocol will compare 24 hour glucose control for subject taking saxagliptin and metformin extended release (XR) versus metformin XR alone
- Trial name
- NCT00683657
- Testing
- Saxagliptin
- Where
- 27 sites in United States, Argentina and 6 more
- Volunteers
- 93 people
- Sponsor
- AstraZeneca
Chronic Spontaneous Urticaria
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
The purpose of this trial is: 1. to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to < 18 years of age suffering from chronic spontaneous urticaria inadequately controlled by…
- Trial name
- NCT05677451
- Testing
- LOU064 (blinded)
- Where
- 49 sites in United States, Argentina and 15 more
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
The purpose of this clinical research study is to learn whether saxagliptin (BMS-477118) is more effective than placebo as a treatment for type 2 diabetic subjects who are not sufficiently controlled with diet and exercise
- Trial name
- NCT00121641
- Testing
- Saxagliptin, Metformin
- Where
- 134 sites in United States, Australia and 4 more
- Volunteers
- 1,035 people
- Sponsor
- AstraZeneca
Generalized Anxiety Disorder
A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD.
- Trial name
- CAR aGAD Ph 2 (NCT04965272)
- Testing
- Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day
- Where
- 36 sites in United States
- Sponsor
- AbbVie
Type 2 Diabetes Mellitus
A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin
This is a randomized, double-blind, placebo-controlled, phase III clinical trial to investigate the efficacy and safety of evogliptin after oral administration in patients with type 2 diabetes who have inadequate glycemic control…
- Trial name
- NCT02946541
- Testing
- evogliptin 5mg
- Where
- South Korea
- Volunteers
- 160 people
- Sponsor
- Dong-A ST Co., Ltd.
Coronary Artery Disease (CAD)
A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)
The purpose of this study is to demonstrate that the strength of agreement between single photon emission computed tomography (SPECT) imaging with regadenoson following inadequate exercise stress testing and SPECT imaging with…
- Trial name
- EXERRT (NCT01618669)
- Testing
- Regadenoson, Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
- Where
- 69 sites in United States, Argentina and 2 more
- Volunteers
- 1,147 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Diabetes Type 2
Safety Study of BMS-770767 in Subjects With Type 2 Diabetes
The purpose of this study is to determine if BMS-770767 is safe, well tolerated, measure its levels in the blood (pharmacokinetics), and measure the levels of chemicals (biomarkers) that may be affected by this drug…
- Trial name
- NCT01046422
- Testing
- BMS-770767, Metformin
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 76 people
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes Mellitus
Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)
This is a study to assess the safety and efficacy of the addition of ipragliflozin once daily in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on sitagliptin, diet, and exercise…
- Trial name
- NCT02577003
- Testing
- Ipragliflozin, Sitagliptin
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes
This is a Phase 2a study designed to assess the safety and tolerability of MEDI0382 titrated up to a dose level of 100, 200 or 300 µg from 50 µg vs Placebo across 48 days in Japanese subjects.
- Trial name
- NCT03645421
- Testing
- MEDI0382 100 μg, MEDI0382 200 μg, MEDI0382 300 μg
- Where
- 5 sites in Japan
- Volunteers
- 61 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes
The purposes of this study is to evaluate the efficacy and safety of SYR-472 when administered at a dose of 100 mg once weekly as an add-on to insulin therapy compared with placebo in patients with type 2 diabetes mellitus and…
- Trial name
- NCT02324569
- Testing
- SYR-472
- Where
- 65 sites in Japan
- Volunteers
- 240 people
- Sponsor
- Takeda
Rheumatoid Arthritis
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in…
- Trial name
- SELECT- SWITCH (NCT05814627)
- Testing
- Upadacitinib, Adalimumab
- Where
- 218 sites in United States, Argentina and 23 more
- Volunteers
- 487 people
- Sponsor
- AbbVie
Type 2 Diabetes Mellitus
Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)
The purpose of this study is to assess the efficacy of omarigliptin 25 mg weekly (as monotherapy) compared with sitagliptin 50 mg daily and placebo, and the long term safety (up to 52 weeks) of omarigliptin 25 mg weekly.
- Trial name
- NCT01703221
- Testing
- Omarigliptin, Sitagliptin
- Volunteers
- 414 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
This randomized, double-blind, parallel-group study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in combination with methotrexate versus RoActemra/Actemra monotherapy in patients with rheumatoid…
- Trial name
- NCT01399697
- Testing
- methotrexate, tocilizumab [RoActemra/Actemra]
- Where
- 54 sites in Spain
- Volunteers
- 261 people
- Sponsor
- Hoffmann-La Roche